Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species
Open Access
- 3 June 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11), 6044
- https://doi.org/10.3390/ijms22116044
Abstract
SGLT-2i’s exert direct anti-inflammatory and anti-oxidative effects on resting endothelial cells. However, endothelial cells are constantly exposed to mechanical forces such as cyclic stretch. Enhanced stretch increases the production of reactive oxygen species (ROS) and thereby impairs endothelial barrier function. We hypothesized that the SGLT-2i’s empagliflozin (EMPA), dapagliflozin (DAPA) and canagliflozin (CANA) exert an anti-oxidative effect and alleviate cyclic stretch-induced endothelial permeability in human coronary artery endothelial cells (HCAECs). HCAECs were pre-incubated with one of the SGLT-2i’s (1 µM EMPA, 1 µM DAPA and 3 µM CANA) for 2 h, followed by 10% stretch for 24 h. HCAECs exposed to 5% stretch were considered as control. Involvement of ROS was measured using N-acetyl-l-cysteine (NAC). The sodium-hydrogen exchanger 1 (NHE1) and NADPH oxidases (NOXs) were inhibited by cariporide, or GKT136901, respectively. Cell permeability and ROS were investigated by fluorescence intensity imaging. Cell permeability and ROS production were increased by 10% stretch; EMPA, DAPA and CANA decreased this effect significantly. Cariporide and GKT136901 inhibited stretch-induced ROS production but neither of them further reduced ROS production when combined with EMPA. SGLT-2i’s improve the barrier dysfunction of HCAECs under enhanced stretch and this effect might be mediated through scavenging of ROS. Anti-oxidative effect of SGLT-2i’s might be partially mediated by inhibition of NHE1 and NOXs.Funding Information
- Chinese Scholarship Council (201906210054)
This publication has 48 references indexed in Scilit:
- Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Journal of the American College of Cardiology, 2021
- Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection FractionJournal of Invasive Cardiology, 2020
- Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart FailureJACC: Cardiovascular Imaging, 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureThe New England Journal of Medicine, 2020
- European Society of Cardiology: Cardiovascular Disease Statistics 2019European Heart Journal, 2019
- Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescenceJournal of Cellular and Molecular Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2019
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary arteryAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2015
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJournal of Invasive Cardiology, 2013